Spatial distribution of tumor-associated macrophages in an orthotopic prostate cancer mouse model
In this study, we investigated the spatial density of innate immune cell populations within NOD.SCID orthotopic prostate cancer xenografts following microinjection of human DU145 prostate cancer cells. Our laboratory has previously developed nanoscale liposomes that attach to leukocytes via conjugated E-selectin (ES) and kill cancer cells via TNF-related apoptosis inducing ligand (TRAIL). Immunohistochemistry (IHC) staining was performed on tumor samples to identify and quantify leukocyte infiltration for different periods of tumor growth and E-selectin/TRAIL (EST) liposome treatments. We examined the spatial-temporal dyna...
Source: Cell Research - May 1, 2024 Category: Cytology Authors: Korie A Grayson Joshua D Greenlee Lauren E Himmel Lauren A Hapach Cynthia A Reinhart-King Michael R King Source Type: research
Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy
CONCLUSION: We developed and validated a novel [18 F]PSMA-1007 PET-based clinical-radiomics model that can predict BRFS following RP in prostate cancer patients. This model may be useful in identifying patients with a higher risk of BCR, thus enabling personalized risk stratification and tailored management strategies.PMID:38691111 | DOI:10.1007/s00259-024-06734-6 (Source: Molecular Medicine)
Source: Molecular Medicine - May 1, 2024 Category: Molecular Biology Authors: Tiancheng Li Mimi Xu Shuye Yang Guolin Wang Yinuo Liu Kaifeng Liu Kui Zhao Xinhui Su Source Type: research
Spatial distribution of tumor-associated macrophages in an orthotopic prostate cancer mouse model
In this study, we investigated the spatial density of innate immune cell populations within NOD.SCID orthotopic prostate cancer xenografts following microinjection of human DU145 prostate cancer cells. Our laboratory has previously developed nanoscale liposomes that attach to leukocytes via conjugated E-selectin (ES) and kill cancer cells via TNF-related apoptosis inducing ligand (TRAIL). Immunohistochemistry (IHC) staining was performed on tumor samples to identify and quantify leukocyte infiltration for different periods of tumor growth and E-selectin/TRAIL (EST) liposome treatments. We examined the spatial-temporal dyna...
Source: Pathology Oncology Research - May 1, 2024 Category: Pathology Authors: Korie A Grayson Joshua D Greenlee Lauren E Himmel Lauren A Hapach Cynthia A Reinhart-King Michael R King Source Type: research
Inter-fractional error and intra-fractional motion of prostate and dosimetry comparisons of patient position registrations with versus without fiducial markers during treatment with carbon-ion radiotherapy
AbstractA few reports have discussed the influence of inter-fractional position error and intra-fractional motion on dose distribution, particularly regarding a spread-out Bragg peak. We investigated inter-fractional and intra-fractional prostate position error by monitoring fiducial marker positions. In 2020, data from 15 patients with prostate cancer who received carbon-ion beam radiotherapy (CIRT) with gold markers were investigated. We checked marker positions before and during irradiation to calculate the inter-fractional positioning and intra-fractional movement and evaluated the CIRT dose distribution by adjusting t...
Source: Radiological Physics and Technology - May 1, 2024 Category: Physics Source Type: research
Absence of causal relationship between Parkinson ’s disease and subsequent prostate cancer: Evidence from meta-analysis and Mendelian randomization studies
Background: Numerous observational studies have investigated the risk of prostate cancer (PCa) in patients diagnosed with Parkinson ’s Disease (PD). However, the existence of a definitive association remains uncertain. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: J.-Y. Deng, X.-M. Wang Source Type: research
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm?
Most men with newly appreciated metastatic prostate cancer are optimally treated with a backbone consisting of androgen receptor–directed therapy with or without taxane chemotherapy. Despite improvements in disease outcomes, prostate cancer remains an extremely heterogeneous disease with variable mechanisms of therapeutic resistance. As a result, it remains a leading cause of cancer-related death in men. Radiopharmaceutical therapy has emerged as an alternative, non–androgen receptor–directed treatment modality for metastatic castration-resistant prostate cancer that impacts patient survival and represent...
Source: Journal of Nuclear Medicine - May 1, 2024 Category: Nuclear Medicine Authors: Viscuse, P., Devitt, M., Dreicer, R. Tags: Continuing Education Source Type: research
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner-Collimator Configurations for 223Ra-Based Radiopharmaceutical Therapies
Personalized dose-based treatment planning requires accurate and reproducible noninvasive measurements to ensure safety and effectiveness. Dose estimation using SPECT is possible but challenging for alpha (α)-particle–emitting radiopharmaceutical therapy (α-RPT) because of complex -emission spectra, extremely low counts, and various image-degrading artifacts across a plethora of scanner–collimator configurations. Through the incorporation of physics-based considerations and skipping of the potentially lossy voxel-based reconstruction step, a recently developed projection-domain low-count quantitativ...
Source: Journal of Nuclear Medicine - May 1, 2024 Category: Nuclear Medicine Authors: Li, Z., Benabdallah, N., Luo, J., Wahl, R. L., Thorek, D. L. J., Jha, A. K. Tags: Basic Science Investigations Source Type: research
Cancers, Vol. 16, Pages 1757: snRNAs from Radical Prostatectomy Specimens Have the Potential to Serve as Prognostic Factors for Clinical Recurrence after Biochemical Recurrence in Patients with High-Risk Prostate Cancer
The objective of this study was to identify biomarkers in formalin-fixed paraffin-embedded (FFPE) RP samples that are prognostic for CR in patients with HRPC who experience BCR after RP (post-RP BCR). First, we performed a preliminary RNA sequencing analysis to comprehensively profile RNA expression in FFPE RP samples obtained from patients with HRPC who developed CR after post-RP BCR and found that many snRNAs were very abundant in preserved FFPE samples. Subsequently, we used quantitative polymerase chain reaction (qPCR) to compare the expression levels of highly abundant snRNAs in FFPE RP samples from patients with HRPC...
Source: Cancers - May 1, 2024 Category: Cancer & Oncology Authors: Hikaru Mikami Syunya Noguchi Jun Akatsuka Hiroya Hasegawa Kotaro Obayashi Hayato Takeda Yuki Endo Yuka Toyama Hiroyuki Takei Go Kimura Yukihiro Kondo Toshihiro Takizawa Tags: Article Source Type: research
De Novo Metastatic Prostate Cancer Presenting With Atypical Lower-Limb Skeletal Metastases Detected on 68Ga-PSMA PET/CT
We present an 86-year-old man with undiagnosed prostate cancer presenting with unilateral foot pain. CT and MRI demonstrated a sclerotic midfoot suggestive of an infiltrative process. In view of an elevated PSA, metastatic disease was suspected, and bone scan confirmed osteoblastically active pelvic and lower-limb skeletal lesions. Subsequent prostate biopsy confirmed prostate adenocarcinoma. Staging 68Ga-PSMA PET/CT demonstrated PSMA-avid intraprostatic malignancy with pelvic and right lower-limb skeletal metastases. This is an unusual case of de novo 68Ga-PSMA-avid metastatic prostate cancer with atypical lower-limb skel...
Source: Clinical Prostate Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Alexander Yip June Yap Source Type: research
Free TcO4- in 99mTc-PSMA Scan: A Case Report and Review of an Old Pitfall in the New Era of Modern Imaging
Clin Nucl Med. 2024 Apr 30. doi: 10.1097/RLU.0000000000005240. Online ahead of print.ABSTRACTIn a recent 99mTc-HYNIC-PSMA study conducted at our department, we examined 2 patients with prostate cancer referred for initial staging on the same day. The whole-body scans revealed radiotracer uptake in the gastric mucosa and thyroid glands, alluding to high levels of free TcO4- in the injected vial. The scans were repeated after confirming acceptable radiopharmaceutical purity of 97% (normal range, 95%-100%). Interestingly, 1 patient had liver metastases at presentation, which remained non-PSMA-avid after repeating the scan. We...
Source: Clinical Prostate Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Pegah Sahafi Kamran Aryana Soroush Zarehparvar Moghadam Kayvan Sadri Emran Askari Source Type: research
Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs
J Clin Invest. 2024 Apr 30:e168649. doi: 10.1172/JCI168649. Online ahead of print.ABSTRACTOne critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and constitutively active AR splice variants, particularly AR-V7. While AR-V7 has been intensively studied, its ability to activate distinct biological functions compared to the full-length AR (AR-FL), and its role in regulating the metastatic progression of castration-resistant PCa (CRPC), remains unclear. Our study found that, under castrated conditions, AR-V7 ...
Source: Clinical Prostate Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Dong Han Maryam Labaf Yawei Zhao Jude Owiredu Songqi Zhang Krishna Patel Kavita Venkataramani Jocelyn S Steinfeld Wanting Han Muqing Li Mingyu Liu Zifeng Wang Anna Besschetnova Susan Patalano Michaela J Mulhearn Jill A Macoska Xin Yuan Steven P Balk Peter Source Type: research
Alpha and Beta Radiation for Theragnostics
PET Clin. 2024 Apr 29:S1556-8598(24)00021-X. doi: 10.1016/j.cpet.2024.03.006. Online ahead of print.ABSTRACTTargeted radionuclide therapy (TRT) has significantly evolved from its beginnings with iodine-131 to employing carrier molecules with beta emitting isotopes like lutetium-177. With the success of Lu-177-DOTATATE for neuroendocrine tumors and Lu-177-PSMA-617 for prostate cancer, several other beta emitting radioisotopes, such as Cu-67 and Tb-161, are being explored for TRT. The field has also expanded into targeted alpha therapy (TAT) with agents like radium-223 for bone metastases in prostate cancer, and several othe...
Source: Clinical Prostate Cancer - April 30, 2024 Category: Cancer & Oncology Authors: Hong Song George Sgouros Source Type: research
Exploring the Antitumor Efficacy of PEGylated Liposomes Loaded with Licorice Extract for Cancer Therapy
CONCLUSION: These results have been corroborated by apoptosis assays, which have demonstrated GA PEG-Lip and Lic PEG-Lip to induce stronger apoptotic effects compared to free GA and Lic on both PC-3 and AGS cells. This study has underscored the potential of encapsulating GA and Lic in PEG-Lip as a promising strategy to augment their anticancer efficacy against prostate and gastric cancers.PMID:38685810 | DOI:10.2174/0115680096292153240416115744 (Source: Current Cancer Drug Targets)
Source: Current Cancer Drug Targets - April 30, 2024 Category: Cancer & Oncology Authors: Zeinab Azizi Haghighat Aliakbar Safekordi Mehdi Ardjmand Azim Akbarzadeh Source Type: research
In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1
This study combined in silico and in vitro methods to identify drugs inhibiting CYP17A1. The most potent CYP17A1 inhibitors identified are serdemetan, mocetinostat, nolatrexed, liarozole, and talarozole. While some of these drugs are currently under investigation for the treatment of various cancers, their potential for the treatment of prostate cancer is yet to be explored. The DrugBank database was screened for CYP17A1 inhibitors, to increase the awareness for the risk of drug-induced pseudohyperaldosteronism and to highlight drugs so far unknown for their potential to cause side effects resulting from CYP17A1 inhibition...
Source: Toxicology and Applied Pharmacology - April 30, 2024 Category: Toxicology Authors: Jacek K ędzierski Marie-Christin J äger Sadaf Naeem Alex Odermatt Martin Smieko Source Type: research
Correction to: High-grade prostate cancer demonstrates preferential growth in the cranio-caudal axis and provides discrimination of disease grade in an MRI parametric model
Br J Radiol. 2024 Apr 30:tqae083. doi: 10.1093/bjr/tqae083. Online ahead of print.NO ABSTRACTPMID:38685713 | DOI:10.1093/bjr/tqae083 (Source: The British Journal of Radiology)
Source: The British Journal of Radiology - April 30, 2024 Category: Radiology Source Type: research
